Skip to main content
. 2020 Nov 24;9:e61981. doi: 10.7554/eLife.61981

Figure 3. Availability of reagents.

Figure 3.

(A) Drugs studied in COVID-19 related clinical trials are frequently studied within the non-COVID-19 literature. We compare non-COVID-19 publications measured for human protein-coding genes that are not listed as pharmaceutical targets in DrugBank (ocher, No drug), against those that are listed as pharmaceutical targets but have not occurred as an intervention in a clinical trial on COVID-19 (orange, Drug no trial), and against those that are listed as pharmaceutical targets and have occurred as an intervention in a clinical trial on COVID-19 (green, Drug and trial). Notches indicate 95% confidence interval of the median. P-values are calculated via Mann-Whitney U test. (B) Fraction of genes with reported usage of an antibody to detect the encoded protein as a prey in BioGRID. Bars are genes identified by the four different genome-wide studies that have either been tagged in the COVID-19 literature (red) or ignored (blue). Error bars indicate 95% confidence interval. P-values are calculated via Fisher’s exact test.